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ABSTRACT 
Background: Osteogenesis imperfecta (OI), the commonest inherited bone fragility disorder, 
affects 1 in 15,000 live births resulting in frequent fractures and reduced mobility, with 
significant impact on quality of life. Early diagnosis is important, as therapeutic advances can 
lead to improved clinical outcome and patient benefit.  
Report: Whole exome sequencing in patients with OI identified, in two patients with a multi-
system phenotype, compound heterozygous variants in NBAS (Neuroblastoma amplified 
sequence). Patient 1: NBAS c.5741G>A p.(Arg1914His); c.3010C>T p.(Arg1004*) in a 10-
year old boy with significant short stature, bone fragility requiring treatment with 
bisphosphonates, developmental delay and immunodeficiency. Patient 2: NBAS c.5741G>A 
p.(Arg1914His); c.2032C>T p.(Glu678*) in a 5-year old boy with similar presenting features, 
bone fragility, mild developmental delay, abnormal liver function tests and 
immunodeficiency.  
Discussion: Homozygous missense NBAS variants cause SOPH syndrome (Short stature; 
Optic atrophy; Pelger-Huet anomaly), the same missense variant was found in our patients on 
one allele and a nonsense variant in the other allele. Recent literature suggests a multi-system 
phenotype. In this study, patient fibroblasts have shown reduced collagen expression, 
compared to control cells and RNAseq studies, in bone cells show that NBAS is expressed in 
osteoblasts and osteocytes of rodents and primates. These findings provide proof-of-concept 
that NBAS mutations have mechanistic effects in bone, and that NBAS variants are a novel 
cause of bone fragility, ZKLFKLVGLVWLQJXLVKDEOHIURPµ&ODVVLFDO¶2, 
Conclusions: Here we report on variants in NBAS, as a cause of bone fragility in humans, 
and expand the phenotypic spectrum associated with NBAS. We explore the mechanism 
underlying NBAS and the striking skeletal phenotype in our patients. 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  Balasubramanian et al 
 3 
KEYWORDS:  bone fragility; Osteogenesis imperfecta; NBAS; nonsense mediated decay 
(NMD); secretory pathway; collagen expression 
 
INTRODUCTION 
NBAS (Neuroblastoma-amplified sequence), also previously referred to as NAG 
(Neuroblastoma-amplified gene) contains 52 exons, spans 420 kb and is mapped to 
chromosome 2p24.3 [1] (Scott et al., 2003). It was initially identified as a gene co-amplified 
with the N-myc (MYCN) gene in neuroblastoma cell lines [2] (Wimmer et al., 1999). NBAS 
was initially described as a novel factor involved in the nonsense mediated (NMD) decay 
pathway in human cells, in zebrafish and in nematodes [3,4] (Longman et al., 2007; 
Anastasaki et al., 2010). It was shown that NBAS acts in concert with core NMD factors to 
co-regulate a large number of endogenous RNA targets [5] (Longman et al., 2013). 
Subsequently, NBAS was also identified as a component of the syntaxin 18 complex, which 
is involved in Golgi-to-endoplasmic reticulum (ER) retrograde transport [6, 7] (Aoki et al., 
2009; Spang A., 2013). NBAS is also said to be an important component of the ER tethering 
complex [8] (Hong WJ and Lev S., 2014).  Using whole exome sequencing, we identified 
compound heterozygous variants in NBAS  in two patients with bone fragility: Patient 1 
presented with significant short stature, bone fragility requiring treatment with 
bisphosphonates, developmental delay and immunodeficiency and was independently 
investigated for a novel cause of bone fragility (having tested negative for all published 
variants in OI). Patient 2 was recruited to the Deciphering Developmental Disorders (DDD) 
study and underwent trio whole exome sequencing.  
Homozygous missense variants in NBAS have been implicated in a hereditary short stature 
syndrome referred to as SOPH syndrome (Short stature; Optic atrophy; Pelger-Huet anomaly) 
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observed in the Yakut Siberian population isolate [9] (Maksimova et al., 2010). Compound 
heterozygous mutations in NBAS have also been described in acute onset liver failure [10] 
(Haack et al., 2015). Further reports have suggested a multi-system phenotype [11,12,13] 
(Segarra NG et al., 2015; Capo-Chichi et al., 2015; Staufner et al., 2016). Bone fragility 
severe enough to need bisphosphonate therapy has not reported as a feature, so far, in 
association with NBAS.  Therefore, we propose that compound heterozygous mutations in 
NBAS can account for a significant form of bone fragility and needs to be considered in the 
differential diagnosis of osteogenesis imperfecta (OI).  
 
CLINICAL REPORT 
Patient 1: This 10-year old boy is the second child of healthy, non-consanguineous parents, 
of North European origin, with no significant family history. He was born by spontaneous 
breech delivery at 33 weeks gestation following a normal pregnancy, with a birth weight of 
1.75kg (9th centile). He required continuous positive airway pressure ventilation (CPAP) for 
24 hours and phototherapy for jaundice. He had recurrent infections and significant problems 
with his feeding, requiring percutaneous gastrostomy insertion to maintain adequate nutrition. 
He had recurrent admissions to hospital with infections including severe recurrent shingles 
with worsening of liver function during infectious episodes and consequent progressive 
lymphopenia and hypogammaglobulinaemia requiring immunoglobulin replacement. He was 
diagnosed with a horizontal nystagmus, bilateral optic atrophy and myopia, needing 
corrective glasses, but his hearing was reported as normal. He has moderate intellectual 
disability and growth parameters remain well below the 0.4th centile. In early childhood, he 
went on to sustain fractures of his tibia and metatarsals, following minimal trauma and has 
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discoloured teeth. He attends an integrated play school, as he has been diagnosed with an 
autism spectrum disorder.  
On examination at 9-years of age, he was dysmorphic, with proptosis, progeric appearance to 
his skin, bilateral low-set ears, dentinogenesis imperfecta, and bilateral 5th finger clinodactyly 
with bulbous tips to his fingers and toes (Figure 1a-e). He has a high-pitched voice and 
growth parameters at 7 years of age were: weight ~ 13.1kg (<0.4th centile), height ~ 88cms 
(<<0.4th centile), head circumference ~ 49.5cms (0.4th-2nd centile), with no evidence of 
asymmetry. Repeat cranial ultrasounds and MRI-brain scans did not show any evidence of 
ventricular dilatation despite initial concerns regarding a large anterior fontanelle. A 
dysplasia skeletal survey showed multiple Wormian bones, slender tubular bones and 
osteopenia (Figure 2a-d). A transiliac bone biopsy at 7-years of age, following recurrent low-
trauma fractures, demonstrated osteoporosis with high bone turnover with marked periosteal 
bone resorption, which was different to appearances in classical OI (Figure 3a-b). In terms of 
his skeletal phenotype, he had a tender back with loss of vertebral height on lateral spine 
radiograph and a low lumbar bone mineral areal density (BMAD) with a Z-score of -3.5 at 9-
years of age. He was commenced on Pamidronate with remarkable improvement to his bone 
health. Collagen species analysis on SDS-Page gel was normal with no obvious shift, but 
electron microscopy showed multiple small collagen flowers, variable shaped collagen fibrils 
with a mean collagen fibril diameter (CFD) of 75nm (Figure 3c-d). Genetic testing so far 
included: normal 60K ArrayCGH, FRAX, UPD7 and 11p15 methylation testing, targeted 
exome panel including all published genes known to cause bone fragility, all of which were 
reported as negative. 
 
Patient 2: This 6-year old boy is the first child of healthy, non-consanguineous parents 
(mother is of Northern-Spanish origin whilst father is of Italian origin) with no significant 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  Balasubramanian et al 
 6 
family history. He was born at 38 weeks gestation, by spontaneous delivery following a 
normal pregnancy with a birth weight of 2.44kg (2nd centile). He did not need to go to Special 
Care Baby Unit but went on to develop a spiral fracture of his left femur whilst being 
positioned for a feed at 3-months of age. A skeletal survey performed at the time showed 
osteopenic slender bones, thin skull vault with a large anterior fontanelle, but no Wormian 
bones. These features were thought to be consistent with but not completely diagnostic of 
type IV OI. He had recurrent infections, problems with his feeding and poor weight gain. He 
also went on to develop recurrent episodes of ketotic hypoglycaemia, which resolved 
spontaneously and hypogammaglobulinaemia, needing 2-weekly immunoglobulin infusions. 
He was diagnosed with abnormal liver function when he had several episodes of temporarily 
elevated transaminases triggered by infections. He was diagnosed with a horizontal 
nystagmus and bilateral optic atrophy, but his hearing was reported to be normal. He has mild 
intellectual disability, managing in mainstream school with 1-to-1 help. His growth 
parameters remain below the 0.4th centile, with some preservation of head circumference 
(0.4th-2nd centile).  
On examination at 5-years of age, he was dysmorphic, with brachycephaly, proptosis, 
progeric appearance to his skin, bilateral low-set ears, greyish sclerae, and bilateral 5th finger 
clinodactyly with bulbous tips to his fingers and toes (Figure 4a-c). He has a high-pitched, 
distinctive voice and growth parameters were: weight ~ 14.4kg (<0.4th centile), height ~ 
96.9cms (<0.4th centile), head circumference ~ 49.6cms (0.4th-2nd centile), with no evidence 
of asymmetry. Repeat cranial ultrasounds, in view of persistent large anterior fontanelle, and 
a MRI-brain scan at one year of age showed non-specific white matter changes, but otherwise 
normal appearances. In terms of his skeletal phenotype, he has gone on to sustain stress 
fractures of his feet, diagnosed on bone scan and a low lumbar bone mineral areal density 
(BMAD) with a Z-score of -4.01 at 5-years of age. He has recently been started on 
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Pamidronate with a good response to therapy. A dysplasia skeletal survey subsequently 
confirmed similar features as reported previously (Figure 4d-e). Genetic testing so far 
included: normal 60K ArrayCGH, targeted exome panel including genes known to cause OI, 
all of which were reported as negative. He was subsequently recruited to the DDD study 
(Decipher Patient ID: 264693). 
 
MATERIALS AND METHODS 
Patient 1 was recruited into a research project to study atypical forms of OI, to establish 
genotype: phenotype correlations therein.  Ethical approval was obtained from the local 
regional ethics committee (LREC) to undertake phenotyping and genetic work-up in this 
group of patients.  Patient 2 was recruited to the DDD study. 
 
DNA Sequencing and mutation analysis in Patient 1: 
Total genomic DNA was isolated from 2 to 5 ml peripheral blood using standard extraction 
methods. Whole exome sequencing was performed by Personalis using their ACE ExomeTM 
Assay. The data were analysed with the Personalis ACE pipeline; this uses BWA (version 
number 0.7.5a-r405) IRUDOLJQPHQW*$7.¶V8QLIiedGenotyper for variant calling and 
*$7.¶V9465WRSURYLGHDVLWHTXDOLW\VFRUHXVLQJWKHVLQJOHSDWLHQWVDPSOH7KHDYHUDJH
depth in the target region was 115X. Variants were extensively annotated with AnnoL, a 
Personalis tool. The annotation includes frequencies by subpopulation from 1000 genomes 
and the Exome Sequencing Project; information from dbNSFP; predicted mutational impacts 
from tools including SIFT, Polyphen2 and MutationTaster; known associations from disease 
databases such as OMIM, ClinVar and the GWAS Catalog; and data from pathway and 
network tools including Reactome and MINT. Calls were quality filtered by Personalis and 
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variants reported at >1% in any of the subpopulations were excluded. Personalis was supplied 
with clinical features of the patient and used these in ranking variants, taking into account the 
similarity in features with reported disease-causing mutations in the same gene. Evidence for 
the top ranking variants was manually reviewed by Personalis to reduce the list to potentially 
causative variants.  
Additionally, the full set of variants reported by Personalis was investigated using their 
annotation. Quality control was carried out using the following hard filters, as recommended 
by the GATK best practice guidelines when there are exome sequences for less than 30 
samples plus an extra filter on genotype quality: for SNVs, QD < 2, MQ < 40, FS > 60, 
HaplotypeScore > 13, MQRankSum < -12.5, ReadPosRankSum < -8; for Indels, QD < 2, 
ReadPosRankSum < -20, FS > 200. Population frequencies from the Exome Aggregation 
Consortium (ExAC, version 0.3) were used in filtering. Only passed ExAC variants were 
used and alleles at multiallelic sites were left aligned to ensure they could be matched with 
the patient data. The number of ExAC individuals in a sub-population that are genotyped at a 
site can be low, meaning that the frequency is estimated with a large error. Therefore, from 
the ExAC set only variants that had a frequency >5% in any subpopulation (excluding the 
µRWKHU¶SRSXODWLRQRURI!1% with a total allele count >1000 were retained. These variants 
were filtered out from the Personalis dataset. Variants reported with a frequency > 1% in any 
of the 1000 genomes, NHLBI ESP or UK10K cohort populations were also excluded. After 
filtering, those variants annotated as frameshift, splice site acceptor, splice site donor, or stop 
gained were extracted and are described as loss of function (LoF) variants. Finally, a larger 
group of variants annotated within a targeted gene list was compiled, which are described as 
targeted missense variants. The targeted gene list consisted of genes reported in connection 
with skeletal dysplasia, identified in GWAS studies to be associated with a change in bone 
density, implicated in bone metabolism in mouse models, and genes with human phenotype 
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ontology terms relating to increased susceptibility to fracture (HPO:0002659), and totalled 
approximately 600 genes. The LoF and targeted missense variants were manually reviewed, 
including looking for compound heterozygotes, to assess whether they might contribute to the 
SDWLHQW¶VSKHQRW\SH. 
 
DNA Sequencing and mutation analysis in Patient 2:  
Trio-based exome sequencing was performed for Patient 2 and his parents as part of the DDD 
study, as previously described [14, 15] (Wright et al., 2015; DDD Study., Nature 2015). 
Putative de novo and inherited variants were identified from exome data using DeNovoGear 
software [15, 16] (Ramu et al., 2013; DDD Study., Nature 2015) and were validated using 
targeted Sanger sequencing.  
 
Western Blot Human primary fibroblasts (HPF) on Patient 1: 
HPF was grown in fully supplemented AmnioMAX C-100 media (Gibco) in hypoxic 
conditions. Prior to lysis, cells were washed twice with PBS and lysed for 20 min at 4 °C in 
IP buffer (10 mM Tris-HCl [pH 8], 150 mM NaCl, 1 mM EGTA, 1% NP-40, 0.2% Na-
Deoxycholate, Complete Protease Inhibitor (Roche), 1 mM DTT. Proteins were resolved by 
SDS-PAGE using 3%±8% Tris-Acetate gel (Life Technologies) and analysed for the 
presence of NBAS by probing with NBAS antibody (Abcam). Uniform protein loading was 
confirmed by probing with tubulin antibody (TUB 2.1, Sigma-Aldrich).  
 
Microscopic analysis of collagen in cultured fibroblasts in Patient 1: 
NBAS patient 1 cultured fibroblasts and control sample were grown for 3 days in 96 well 
plates, fixed and stained with anti-Col1A1 antibody (green) and Hoechst (blue) and imaged 
using a high content microscope. 
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RESULTS 
Patient 1: Personalis reported four top ranking variants. Two were heterozygous variants in 
the NBAS, c.5741G>A p.(Arg1914His) and c.3010C>T p.(Arg1004*) (Figure 5a). The 
impact of the variants was determined for transcript NM_015909.3. The potential pathogenic 
effect of the missense variant and nonsense variant were assessed using Alamut Visual 
version 2.6 (Interactive Biosoftware, Rouen, France) and the Association of Clinical Genetic 
Science best practice guidelines for the evaluation of pathogenicity and the reporting of 
sequence variants in clinical molecular genetics.  
The other two variants did not appear contributory to the phenotype and were of uncertain 
significance; a novel heterozygous variant of uncertain significance in ARID1B, 
c.1041_1043dupGGC (p.Ala350dup), and another heterozygous novel variant of uncertain 
significance in SKIV2L, c.3404T>C (p.Ile1135Thr). Previously reported pathogenic 
variants in ARID1B associated with autosomal dominant mental retardation type 12 include 
nonsense and frameshifting insertions/deletions which result in haploinsufficiency [17] 
(Hoyer et al., 2012). c.1041_1043dupGGC (p.Ala350dup), is an in-frame duplication variant 
in exon 1 of the ARID1B gene which results in the addition of one extra alanine to a stretch of 
11 consecutive alanine residues. The product of the ARID1B gene plays a role in chromatin 
remodeling for transcriptional activation and repression of select genes. To our knowledge, 
variants in this polyalanine tract have not been reported in association with disease. Variants 
in SKIV2L have been previously reported in the literature in association with 
trichohepatoenteric syndrome-2 (THES2), an autosomal recessive disease [18] (Fabre et al., 
2012)+RZHYHUERWKWKHYDULDQWVDUHXQOLNHO\WRDFFRXQWIRU3DWLHQW¶VSKHQRW\SH 
The total number of detected variants was 189,298. After quality and frequency filtering, 
19,772 remained. There were 89 LoF variants, none of which were in genes with an apparent 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  Balasubramanian et al 
 11 
function in bone. There were 23 targeted missense variants that were predicted to be likely 
benign following in-silico analysis.  
The presence of the NBAS variants was confirmed by Sanger sequencing of the proband. 
Sequencing of the parents showed that c.3010C>T p.(Arg1004*)  is present in the mother and 
c.5741G>A p.(Arg1914His) in the father. The c.5741G>A is the same missense variant 
which was described in homozygous form in patients with SOPH syndrome [5] (Maksimova 
et al., 2010). c.3010C>T was reported by Haack et al., 2015 in a compound heterozygous 
form to be associated with acute liver failure [10]. 
Pilot studies of collagen expression and transport in NBAS cells cultured from patients 
described in this study, show that collagen secretion appears reduced and collagen bundles 
appear more diffuse, as compared with control cells consistent with interference with 
trafficking and secretion (Figure 6). Furthermore, Western blot analysis shows reduced level 
of NBAS protein in patients, as compared to control cells (Figure 7). This implies that the 
compound heterozygous mutation reported in this patient, compromises the stability of the 
protein, resulting in a dramatic reduction in NBAS protein levels. 
 
Patient 2: Two heterozygous variants in the NBAS gene were identified, c.5741G>A 
p.(Arg1914His); c.2032C>T p.(Glu678*) (Figure 5b) and segregation analysis showed that 
c.5741G>A p.(Arg1914His) is present in the mother and c.2032C>T p.(Glu678*) is present 
in the father. The c.5741G>A is the same missense variant which was described in 
homozygous form in patients with SOPH syndrome [5] (Maksimova et al., 2010). The 
c.2032>T is a novel variant and has not been reported in HGMD or present in the Exome 
Aggregation Consortium (ExAC) dataset. Western blot analysis of human primary fibroblasts 
(HPF) cultured from patients showed reduced level of NBAS protein in patients, as compared 
to control cells (Figure 7). 
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DISCUSSION 
Osteogenesis imperfecta (OI) is a disease encompassing a group of disorders mainly 
characterised by bone fragility.  There is a broad spectrum of clinical severity in OI, ranging 
from multiple fractures in-utero and perinatal death, to near-normal adult stature and low 
fracture incidence.  Facial dysmorphism has been noted [19] (Gorlin Monographs). Sillence 
et al., in 1979 provided the clinical classification, which has been expanded [20,21] (Sillence 
et al., 1979; Forlino & Marini 2016). Defects in genes encoding type 1 collagen 
(COL1A1/A2) can be identified in 85% of patients with a clinical diagnosis of OI [21,22] ( 
Forlino & Marini 2016; Marini et al., 2013). So far, several other genes have been implicated 
in rare forms of heritable bone fragility including autosomal dominant type V OI (IFITM5), 
X-linked osteoporosis (PLS3 and MBTPS2), autosomal recessive forms (BMP1/ CREB3L1/ 
CRTAP/ FKBP10/ P3H1/ P4HB/ PLOD2/ PPIB/ SEC24D/ SERPINF1/ SERPINH1/ SP7/ 
SPARC/ TMEM38B) and heterozygous mutations in WNT1/ LRP5.  
NBAS (the human neuroblastoma amplified sequence gene) was first isolated using genome 
scanning techniques in neuroblastoma cell lines [1] (Scott et al., 2003). The NBAS protein 
FRQWDLQV:'UHSHDWVȕ-propeller domain; PFAM domain PF00400) in the N-terminal part 
of the protein and a SEC39 domain (PFAM domain PF08314), involved in the secretory 
pathway (Figure 8). Syntaxins play an important role in membrane fusion of transport 
vesicles with the acceptor compartment [23] (Jahn and Scheller. 2006). Although, the exact 
function of NBAS has not been clearly elucidated, it has been shown that a peripheral protein 
encoded by this gene is a sub-unit of the Syntaxin 18 complex [8] (Hong WJ and Lev S., 
2014) involved in golgi-to-endoplasmic reticulum retrograde transport. [6] (Aoki et al., 
2009).  
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There are precedents for defects in the core secretory machinery resulting in human disease. 
Proteins exiting the ER are packaged into COPII transport vesicles which are made up of 
three protein complexes: SAR1, SEC23/SEC24 and SEC13/SEC31 [24] (Jensen and 
Schekman, 2011). Mammalian COPII proteins have been increasingly implicated in human 
disease, [25, 26, 27] (Jones et al., 2003; Boyadjiev et al., 2006; Singleton et al., 2015). In 
human phenotypes, the underlying pathogenesis appears to be due to failure to recruit the 
specific COPII protein, resulting in a large reduction in the packaging of specific cargo 
proteins in vitro, accompanied by swelling of the ER with untransported cargo in vivo in a 
specific tissue [28] (Fromme et al., 2007). 
In the context of bone fragility, SEC24 is mainly responsible for sorting cargo molecules 
through interactions during COPII vesicle assembly. Mutations in SEC24D, a tissue specific 
isoform of the COPII coat is associated with a recessive form of OI [29] (Garbes et al., 2015). 
Evidence to-date suggests that similarly NBAS variants have a cargo-selective, tissue-specific 
phenotype. It has been shown to be localised to the ER; required for Golgi-ER retrograde 
transport and its loss is associated with defects in protein glycosylation. Collagen is a large 
extracellular matrix protein, synthesized in ER as a rigid rod precursor (procollagen which is 
approximately 300 nm in length) and packaged into COPII transport vesicles (which are 
typically 70-100 nm in size). This packaging of collagen requires the transmembrane (TM) 
protein, TANGO1 and the enzymatic activity of CUL3±KLHL12. Jin et al., 2012 showed that 
modification of a COPII protein allows the formation of transport vesicles large enough to 
hold a bulky cargo like procollagen [30,31] (Jin et al., 2012; Stephens et al., 2012). 
Evidence also suggests that NBAS plays a role in nonsense mediated mRNA decay (NMD) 
[5] (Longman et al., 2013). The NMD pathway is a highly-conserved surveillance 
mechanism that selectively degrades mRNAs harbouring premature termination codons 
(PTC), acting to prevent the accumulation of truncated proteins that may interfere with 
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cellular function [32,33] (Chang YF et al., 2007; Isken et al., 2008). NMD also has an 
important role in controlling the expression of many naturally occurring transcripts [34] (Hug 
et al., 2016). NBAS is a bona-fide NMD factor that acts together with core NMD factors to 
regulate expression of  a large number of endogenous RNA targets [5] (Longman et al., 
2013). Interestingly, NBAS-regulated genes harbour sequence features associated with 
protein trafficking and ER-coupled protein modifications. Multiple targets for NBAS appear 
to have a role in regulation of bone mineralisation, osteoblast differentiation and bone 
development. The target with strongest up-regulation upon NBAS-depletion was MGP gene 
(matrix Gla protein), which acts as an inhibitor of bone formation [5] (Longman et al., 2013).  
MGP variants are associated with Keutel syndrome which shows abnormal cartilage 
calcification [35] (Munroe PB et al., 1999). RNAseq studies in bone cells show that NBAS is 
expressed in osteoblasts and osteocytes of rodents and primates.  
CRISPR-Cas9 technology has been used to generate stable knockout NBAS cell lines in 
human SAOS2 osteoblast cells. Further studies are underway to understand the precise 
mechanism of action of NBAS in NMD and secretion, resulting in a multi-system phenotype. 
Since NBAS has been proposed to function in the NMD pathway and Golgi-ER transport, the 
effect on bone fragility could be attributed to either pathway in isolation, or alternatively to a 
combination of both. We propose three possible models to explain how NBAS variants give 
rise to phenotypes and human disease based on the cell studies (WB and high content 
microscopy) and EM findings; 1) due to a compromised Golgi-ER retrograde transport, 2) 
due to an NMD phenotype, 3) a dual role i.e. a compromised Golgi-ER transport indirectly 
affecting NMD. 
Homozygous missense variants c.5741G>A(p.Arg1914His) in NBAS were reported as being 
associated with SOPH syndrome (Short stature with optic atrophy and Pelger-Huet anomaly) 
[9] (Maksimova et al., 2010). Both patients reported here have features of SOPH i.e. short 
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stature, granulocyte left shift with Pelger Huet cells but the facial dysmorphism is distinct as 
explained by the different ethnicity of our patients. Mutations in NBAS were reported in 
individuals with early-onset recurrent acute liver failure, but none of the individuals reported 
had a skeletal phenotype [10] (Haack et al., 2015). More recent literature is suggesting a 
multi-system phenotype with a skeletal phenotype and early-onset osteoporosis [11, 12, 13] 
(Garcia Segarra et al., 2015; Capo-Chichi JM et al., 2015; Staufner et al., 2015). 
Interestingly, our patients also have abnormal liver function tests of unexplained cause, since 
a young age, but have never had any episodes of acute onset liver failure (ALF). In addition, 
our patients also have a predominant skeletal phenotype with bone fragility, multiple 
vertebral (Patient 1) and long bone fractures (Patient 1 and 2) needing treatment with 
Pamidronate. Hence, mutations in NBAS are likely to be a novel cause of heritable bone 
fragility and should be included in the targeted gene panel testing for OI that is currently 
offered in diagnostic genetic testing, in order to clarify diagnosis, inform prognosis and 
discussions around recurrence risk (up to 25%). 
 
SUMMARY 
Bone fragility, severe enough to need therapy in childhood, has not been previously reported 
as a feature associated with variants in NBAS.  Therefore, we hypothesise that compound 
heterozygous variants in NBAS accounts for bone fragility and is a novel cause of 
Osteogenesis Imperfecta (OI). The increasing evidence pointing to a role for NBAS in liver, 
immune and connective tissue coupled with its extreme phenotypic variability make 
understanding NBAS function important.  
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FIGURE LEGENDS 
Figure 1a-e:  1a-c: Facial features as an infant and aged >1, 2 and 9 years showing grey 
sclerae, broad forehead, bilateral low-set ears, proptosis and progeric appearance; 1d-e: 
Hands and feet at 2-years of age. 
Figure 2a-d:  Radiographs demonstrating slender ribs, tubular long bones with thin cortices 
and osteopenia consistent with a diagnosis of OI. 2a: AP skull radiograph (aged 6 years) 
There are multiple Wormian bones; the clavicles are slender and the erupted teeth are 
relatively dense. The anterior fontanelle remains open.  
2b-d: Selected images from a full dysplasia skeletal survey (aged 9 years 8 months) 
2b: Left hand.  There is significant periarticular osteopenia (see Fig 2c). The metacarpals (and 
less marked) the proximal phalanges are overmodelled and there is an ivory epiphysis of the 
terminal phalanx of the fifth finger. The terminal tufts are prominent. 
2c: AP Chest. The ribs and clavicles are slender; however, there are no fractures and vertebral 
body height is preserved. Note the presence of a gastrostomy. 
2d. AP Right Femur: Overmodelled with slender diaphysis and relatively flared distal 
metaphysis. Periarticular osteopenia is again noted (see Fig 2a) 
2e: Peripheral blood film in Patient 1 demonstrating a hypolobulated neutrophil (left) and a 
Pelger-Huet cell (right). 
Figure 3a-b: 3a: Toluidine blue-stained section of an undecalcified trans-iliac bone biopsy, 
original magnification 400x demonstrating cortex, with periosteum on the right showing high 
turnover osteopenia with marked sub-periosteal bone resorption (arrow) and normal lamellar 
bone matrix structure in Patient-DJHG\HDUVEDSSHDUDQFHLQµ&ODVVLFDO2,¶ZLWK
abnormal matrix pattern and increased periosteal bone formation surface (arrow). Toluidine 
blue; Original magnification of 400x. 
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Figure 3c-d: 3c: Electron Microscopy of skin biopsy from Patient 1(left image) compared to 
normal control (middle image) showing normal collagen in mid-reticular dermis with mildly 
reduced mean collagen fibril diameter (CFD); Original magnification of 20,000x; Lower 
magnification (right image) with arrows indicating deep reticular dermal fibroblast with 
expanded protein filled rough endoplasmic reticulum; Original magnification x2,600. 
3d: normal collagen species analysis with no deviation from control (1 and 3) in comparison 
to patient with a COL1A1 variant (2). 
Figure 4a-e: 4a-c: Facial appearance of Patient 2 aged <2, 3 and 5 years demonstrating 
similar facial dysmorphism to Patient 1 with progeric appearance, grey sclerae, broad 
forehead, bilateral low-set ears, proptosis; 4d-e: Skull and right lower limb X-rays 
demonstrating thin skull vault, slender bones and osteopenia. 
Figure 5a and b: Electropherograms (forward sequence) demonstrating NBAS variants in 
Patient 1 compared to normal control and Patient 2 (sequence variant plot).  
Figure 6: NBAS patient 1 cultured fibroblasts (A,B) and control sample (C,D) were grown 
for 3 days in 96 well plates, fixed and stained with anti-Col1A1 antibody (green) and Hoechst 
(blue) and imaged using a high content microscope. (A, B) show increased diffuse 
cytoplasmic staining. Collagen bundles from control (C, D). 
Figure 7: Western blot on Patient 1 and 2 cultured fibroblasts showing reduced NBAS 
protein levels compared to controls; HPF: Human primary fibroblasts. 
Figure 8: Schematic representation of NBAS structure with known protein domains in human 
(blue) and zebrafish (green) protein (shaded boxes represent the regions of sequence 
conservation within proteins; the level of conservation is indicated in percentage). 
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